Zobrazeno 1 - 10
of 32
pro vyhledávání: '"MK Atwood"'
Publikováno v:
Cancer
Background The extent of breast cancer outcome disparity can be measured by comparing Surveillance, Epidemiology, and End Results (SEER) breast cancer‐specific survival (BCSS) by region and with institutional cohort (IC) rates. Methods Patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba0b8cc22d836e5afe8f4835173fa63
https://doi.org/10.1002/cncr.32531
https://doi.org/10.1002/cncr.32531
Publikováno v:
Cancer Research. 79:P1-03
Background: Distant recurrence metastatic breast cancer (rMBC) incidence has declined with coincident improved breast cancer (BC) survival over time. Lead time is time from screening diagnosis to diagnosis that would have been made without screening.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7484da178c5945f6a599ff038c3a75b4
https://doi.org/10.1158/1538-7445.sabcs18-p1-03-01
https://doi.org/10.1158/1538-7445.sabcs18-p1-03-01
Publikováno v:
Cancer Research. 77:P2-06
Background: De novo stage IV and relapsed stage IV metastatic breast cancer (MBC) may present with different biology and respond differentially to treatment. De novo stage IV patients are treatment naive which may confer a survival advantage. Prior r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15bc60858f82bd74f1c6d436ab4eaeab
https://doi.org/10.1158/1538-7445.sabcs16-p2-06-02
https://doi.org/10.1158/1538-7445.sabcs16-p2-06-02
Publikováno v:
Cancer Research. 78:P6-08
Background: It is not known how much de novo MBC (dnMBC) survival varies by where one lives and receives treatment in the US. Variation could exist depending on access to care, insurance availability, geographic area, and treatment options (urban vs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a221d272adf0b43ec72233e8e98eb4a1
https://doi.org/10.1158/1538-7445.sabcs17-p6-08-11
https://doi.org/10.1158/1538-7445.sabcs17-p6-08-11
Publikováno v:
Cancer. 121:2553-2561
BACKGROUND The extent to which improvements over time in breast cancer survival are related to earlier detection by mammography or to more effective treatments is not known. METHODS At a comprehensive cancer care center, the authors conducted a retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93605e2e2d70f3922f6315e25bf178cf
https://doi.org/10.1002/cncr.29371
https://doi.org/10.1002/cncr.29371
Publikováno v:
Leukemia research. 47
Therapy-related myelodysplastic syndrome (t-MDS) is a serious clinical disease occurring after breast cancer treatment.A cohort of 11,684 invasive breast cancer (BC) patients from 1990-2014 were followed for incidence of t-MDS through institutional a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53017baeb4ead20bb1d1fa4d7c71990e
https://pubmed.ncbi.nlm.nih.gov/27614247
https://pubmed.ncbi.nlm.nih.gov/27614247
Publikováno v:
Cancer Research. 71:P4-12
Background: Myelodysplastic syndrome (MDS) has not been well documented or described post breast cancer (BC) treatment. Methods: A cohort of all breast cancer patients from 1989 to 2010 at our institution were followed for incidence of blood disorder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::938e0e25146ca4a884e7925c141866e3
https://doi.org/10.1158/0008-5472.sabcs11-p4-12-11
https://doi.org/10.1158/0008-5472.sabcs11-p4-12-11
Publikováno v:
Cancer Research. 70:P5-10
Background: Adjuvant chemotherapy is not generally recommended for women 75 years and over due to presence of comorbid conditions and lower stage. Methods: We conducted a prospective cohort study of all women presenting with primary breast cancer (BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ea9c7830cc8ca346f1f94814716b6e1
https://doi.org/10.1158/0008-5472.sabcs10-p5-10-14
https://doi.org/10.1158/0008-5472.sabcs10-p5-10-14
Publikováno v:
Cancer Research. 73:P2-04
Background: Federal expenditures continue to increase for Medicare eligible women age 65-74 years. It is hypothesized that the cost of mammography screening may be offset by the reduction in treatment, specifically adjuvant chemotherapy, needed for b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b719d3b50e13ee18f2289d1711494257
https://doi.org/10.1158/0008-5472.sabcs13-p2-04-01
https://doi.org/10.1158/0008-5472.sabcs13-p2-04-01
Publikováno v:
The Breast Journal. 15:454-460
Adjuvant treatment of T1N0 breast cancer (BC) has evolved in recent years with chemotherapy options dependent on tumor size and cellular characteristics. Our goal is to describe the difference in outcome between T1N0 triple negative (TriNeg) and estr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff8da347361fb1e63af46e528f7ab9e
https://doi.org/10.1111/j.1524-4741.2009.00789.x
https://doi.org/10.1111/j.1524-4741.2009.00789.x